Showing results (301-310 of 523) with videos related to
Sort By:
Pageof 53
Chest|December 15, 2006
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.Cancer|August 4, 2005
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary treeAlain Gelibter, Paola Malaguti, Serena Di Cosimo, et al.Annals of Translational Medicine|November 26, 2015
Melanoma: oncogenic drivers and the immune systemNiki Karachaliou, Sara Pilotto, Cristina Teixidó, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2025
Complete Response to Lorlatinib in Lung Adenocarcinoma With EML4-ALK Fusion Variant (E6;A18): Case Report and Literature ReviewAntonio Vitale, Elisa De Paolis, Jacopo Russo, et al.Minerva Surgery|August 2, 2021
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysisArmando Orlandi, Sabatino D'Archi, Giovanna Garufi, et al.Lung Cancer (Amsterdam, Netherlands)|May 16, 2006
Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical casesGiulia Veronesi, Uliano Morandi, Marco Alloisio, et al.Cancers|February 13, 2026
Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung CancerGiovanni Leuzzi, Federica Sabia, Matteo Calderoni, et al.Journal of Experimental & Clinical Cancer Research : CR|October 29, 2023
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB responseBelinda Palermo, Ornella Franzese, Giuseppe Frisullo, et al.Cancer|August 10, 2005
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trialsPaolo Carlini, Emilio Bria, Diana Giannarelli, et al.Cancers|July 2, 2021
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical FeaturesAntonio Passaro, Silvia Novello, Diana Giannarelli, et al.Pageof 53